Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response.
Biomarker development for prediction of patient response to therapy is one of the goals of molecular profiling of human tissues. Due to the large number of transcripts, relatively limited number of samples, and high variability of data, identification of predictive biomarkers is a challenge for data analysis. Furthermore, many genes may be responsible for drug response differences, but often only a few are sufficient for accurate prediction. Here we present an analysis approach, the Convergent Random Forest (CRF) method, for the identification of highly predictive biomarkers. The aim is to select from genome-wide expression data a small number of non-redundant biomarkers that could be developed into a simple and robust diagnostic tool. Our method combines the Random Forest classifier and gene expression clustering to rank and select a small number of predictive genes. We evaluated the CRF approach by analyzing four different data sets. The first set contains transcript profiles of whole blood from rheumatoid arthritis patients, collected before anti-TNF treatment, and their subsequent response to the therapy. In this set, CRF identified 8 transcripts predicting response to therapy with 89% accuracy. We also applied the CRF to the analysis of three previously published expression data sets. For all sets, we have compared the CRF and recursive support vector machines (RSVM) approaches to feature selection and classification. In all cases the CRF selects much smaller number of features, five to eight genes, while achieving similar or better performance on both training and independent testing sets of data. For both methods performance estimates using cross-validation is similar to performance on independent samples. The method has been implemented in R and is available from the authors upon request: Jadwiga.Bienkowska@biogenidec.com.
Bienkowska
Jadwiga R
JR
Biogen IDEC 14 Cambridge Ctr, Cambridge, MA 02142, USA. Jadwiga.Bienkowska@biogenidec.com
Dalgin
Gul S
GS
Batliwalla
Franak
F
Allaire
Normand
N
Roubenoff
Ronenn
R
Gregersen
Peter K
PK
Carulli
John P
JP
D000230:Adenocarcinoma / Q000235:genetics; D000465:Algorithms; D018501:Antirheumatic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood*; D001943:Breast Neoplasms / Q000473:pathology; D016000:Cluster Analysis; D003663:Decision Trees; D018450:Disease Progression; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D055106:Genome-Wide Association Study; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics; D008297:Male; D009362:Neoplasm Metastasis; D020411:Oligonucleotide Array Sequence Analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics; D014158:Transcription, Genetic; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha
BMC Bioinformatics. 2006 Apr 10;7:197
16606446
N Engl J Med. 2006 Aug 10;355(6):560-9
16899776
Rheumatology (Oxford). 2008 Apr;47(4):507-13
18304941
Bioinformatics. 2005 Jan 15;21(2):171-8
15308542
Cancer Res. 2008 Mar 1;68(5):1378-87
18316601
Mod Pathol. 2005 Apr;18(4):547-57
15529185
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S93-9
16273792
BMC Bioinformatics. 2004 Jun 24;5:81
15217521
Nucleic Acids Res. 2006 Feb 01;34(3):765-72
16452299
Arthritis Rheum. 1998 Oct;41(10):1845-50
9778226
Am J Pathol. 2007 Nov;171(5):1419-30
17916599
Genomics. 2008 Nov;92(5):359-65
18672051
Nat Biotechnol. 2006 Sep;24(9):1151-61
16964229
Nature. 2005 Jun 30;435(7046):1262-6
15988529
Cancer Cell. 2002 Mar;1(2):203-9
12086878
J Comput Biol. 2004;11(2-3):227-42
15285890
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9608-13
12869696
Nature. 2002 Jan 31;415(6871):530-6
11823860
Int J Cancer. 2007 Apr 1;120(7):1451-8
17245699
Blood. 2007 Feb 1;109(3):1123-30
17008546
Bioinformatics. 2005 Oct 15;21(20):3940-1
16096348
Int Immunopharmacol. 2006 Nov;6(11):1673-81
16979121
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5355-60
17875763
Nat Biotechnol. 2006 Sep;24(9):1115-22
16964225
BMC Bioinformatics. 2006 Jan 06;7:3
16398926
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5563-8
17372210
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14865-70
16990432
Science. 1999 Oct 15;286(5439):531-7
10521349
J Biol Chem. 1999 Apr 30;274(18):12642-9
10212244